ArticleBMC microbiology2026
First report of Candidozyma auris in Vietnam.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early diagnosis and treatment of Candidozyma auris improve survival. At Cho Ray Hospital, the organism was successfully identified using Vitek 2 and Vitek MS systems. However, antifungal susceptibility testing remains challenging due to the lack of Clinical and Laboratory Standards Institute (CLSI) standards. The Microbiology Department follows provisional United States Centers for Disease Control and Prevention (U.S. CDC) guidelines and uses the broth microdilution method with the Sensititre YeastOne panel for testing. Candidozyma auris showed susceptibility rates of 81.6% to caspofungin, 94.7% to fluconazole, and 71.1% to amphotericin B. No isolates were resistant to all three antifungal classes, while 7.9% were resistant to two classes and 36.8% to one. Susceptibility patterns of 38 isolates were evaluated using both Sensititre YeastOne (microdilution with color) and Etest (agar diffusion), following CDC guidelines, to support method selection based on lab resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.